CinCor Pharma starts clinical trial | Detecting prostate cancer | HealthTech in Flint

December 22, 2021

CINCINNATI, OH—CinCor Pharma, which recently raised $143 million to develop treatments for hypertension and other cardio-renal diseases, has dosed its first patient in a new clinical trial. The High ALdOsterone (HALO) trial assesses the safety and efficacy of CIN-107, a highly selective, oral small molecule inhibitor for patients with uncontrolled hypertension.

OMAHA, NE—Bot Image, a MRI medical device company, announced an addition to its line of software products aimed at assisting the detection of prostate cancer. Called QT Prostate MRI, the new SaaS uses machine learning to produce a colorized map of both normal and abnormal tissue.

PITTSBURGH, PA—AlphaLab Health is a health accelerator based in an old hospital’s former lab space that now houses biotech research, offices for startups, and conference space. The accelerator has announced its second cohort, which will include tech to improve maternal and child health, apply artificial intelligence (AI) and machine learning to neurotrauma, and turn your smart phone into an advanced lung function monitor. (We spoke to two of the innovators who launched AlphaLab Health, Dr. Jeff Cohen and Rich Lunak in September. You can read the interview here.)

FLINT, MI—XLerateHealth has announced an expansion in Michigan, along with new funding sources. The expansion includes the development of a new pre-accelerator program to further prime early stage innovations and entrepreneurs in Flint. Registration for the new program will start in February 2022. Learn more about the program.

BLOOMINGTON, IN—A silicon device that can change skin tissue into blood vessels and nerve cells has advanced from prototype to standardized fabrication. The device, developed by researchers at the Indiana University School of Medicine, comes one step closer to potential use as a treatment for people with a variety of health concerns.